Original Work

581.

Türk, M., Kocatürk, E., Ertas, R., Ensina, L. F., Ferruci, S. M., Grattan, C., Vestergaard, C., Zuberbier, T., Maurer, M.⁺, and Giménez-Arnau, A. M.: A global perspective on stepping down chronic spontaneous urticaria treatment: results of the UCARE SDown-CSU study. Clin. Transl. Allergy 2024: 14; e12343. IF: 4.00

580.

Kovalkova, E.⁺, Fomina, D., Borzova, E., Maltseva, N., Chernov, A., Serdoteckova, S., Weller, K., and Maurer, M.: Сomorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights. J. Allergy Clin. Immunol. Pract. 2024: 12; 482-490. IF: 6.60

579.

Maurer, M., Albuquerque, M., Boursiquot, J.-N., Dery, E., Giménez-Arnau, A., Godse, K., Guitiérrez, G., Kanani, A., Lacuesta, G., McCarthy, J., Nigen, S., and Winders, T.⁺: A patient charter for chronic urticaria. Adv. Ther. 2024: 41; 14-33. IF: 4.00

578.

Maurer, M.⁺, Ensina, L. F., Giménez-Arnau, A. M., Sussman, G., Hide, M., Saini, S., Grattan, C., Fomina, D., Rigopoulos, D., Berard, F., Canonica, G. W., Rockmann, H., Irani, C., Szepietowski, J. C., Leflein, J., Bernstein, J. A., Peter, J., Kulthanan, K., Godse, K., Ardusso, L., Ukhanova, O., Staubach, P., Sinclair, R., Gogate, S., Thomsen, S. F., Tanus, T., Ye, Y. M., Burciu, A., Barve, A., Modi, D., Scoryrev, E., Hua, E., Letzelter, K., Varanasi, V., Patekar, M., Severin, T., and Pearl-1 and PEARL2 trial investigators: Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet 2024: 403; 147-159. IF: 88.50

577.

Mostmans, Y.⁺, Maurer, M., Richert, B., Smith, V., Melsens, K., De Maertelaer, V., Saidi, I., Corazzi, F., and Michel, O.: Chronic spontaneous urticaria: evidence of systemic microcirculatory changes. Clin. Transl. Allergy 2024: 14; e12335. IF: 4.00

576.

Maurer, M.⁺, Lumry, W. R., Li, H. H., Aygören-Pürsün, E., Busse, P. J., Jacobs, J., Nurse, C., Ahmed, M. A., Watt, M., Yu, M., and SPRING Investigators: Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING study. J. Allergy Clin. Immunol. Pract. 2024: 12; 201-2011. IF: 6.60

575.

Salameh, P., Gutsche, A., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and Maurer, M.⁺: Urticaria control test real-world performance: a post hoc analysis. Allergy 2024: 79; 229-232. IF: 12.00

574.

Weller, K., Giménez-Arnau, A. M., Baron, J., Brehler, R., Ferrer, M., Groffik, A., Grundmann, S., Jakob, T., Labrador-Horrillo, M., Müller, S., Staubach, P., Wurpts, G., Metz, M., and Maurer, M.⁺: Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: a randomized trial. Allergy 2024: 79; 93-103. IF: 12.00

573

Moñino-Romero, S., Kolkhir, P., Ohanyan, T., Szépfalusi, Z., Weller, K., Metz, M., Scheffel, J., Maurer, M.⁺, and Altrichter, S.: Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2024: 38; 167-174. IF: 8.00

572.

Neisinger, S.⁺, Sousa Pinto, B., Ramanauskaite, A., Bousquet, J., Weller, K., Metz, M., Magerl, M., Kocatürk, E., Cherrez-Ojeda, I., Giménez-Arnau, A. M., Parisi, C. A. S., Altrichter, S., Ensina, L. F., Bouillet, L., Asero, R., Goncalo, M., Guillet, C., Rutkowski, K., Bernstein, J. A., Hardin, H., Godse, K., Brzoza, Z., Laco Sousa, J. I., Thomsen, S. F., van Doorn, M., Hide, M., Ye, Y.-M., Vanderse, S., Lapina, L., Peter, J., Zhao, Z., Han, L., Nasr, I., Rockmann-Helmbach, H., Astrup Sørensen, J., Öztas Kara, R., Kurjane, N., Kurchenko, A., Kaidashev, I., Tsaryk, V., Stepanenko, R., and Maurer, M.: CRUSE^® – an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clin. Transl. Allergy 2024: e12328. IF: TBD 4.00